Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
What is a Trump Gold Card? U.S. launches $1 million immigration visas - 2Jamaica reports deadly leptospirosis outbreak after Hurricane Melissa
- 3Top Breakfast Food: What's Your Morning Enjoyment?
- 4Picking the Right Air Purifier for Your Home
- 5Uzbekistan launches €9.46 billion green energy push, covering nation’s power needs
- 5 Language Learning Applications
- Mom warns of Christmas gift hazard as daughter recovers in hospital
- CDC advisory panel delays vote on hepatitis B vaccines after unruly meeting
- Here's what can happen if you drive under the influence of pot
- Brazil's former President Jair Bolsonaro seeks house arrest for prison time citing health issues
- How effective is the flu shot this year? New report shows promising results
- Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
- 12 times rockets and spacecraft crashed and burned in 2025
- 6 US States for Fly Fishing
